{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:55:08Z","timestamp":1768035308644,"version":"3.49.0"},"publisher-location":"Cham","reference-count":133,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030576158","type":"print"},{"value":"9783030576165","type":"electronic"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1007\/978-3-030-57616-5_8","type":"book-chapter","created":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T10:04:02Z","timestamp":1603188242000},"page":"105-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Necrotizing Soft Tissue Infections: IVIG"],"prefix":"10.1007","author":[{"given":"Martin Bruun","family":"Madsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Bergsten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Norrby-Teglund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"key":"8_CR1","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/archdischild-2013-304741","volume":"99","author":"S Adalat","year":"2014","unstructured":"Adalat S, Dawson T, Hackett SJ et al (2014) Toxic shock syndrome surveillance in UK children. Arch Dis Child 99:1078\u20131082","journal-title":"Arch Dis Child"},{"key":"8_CR2","volume":"9","author":"MM Alejandria","year":"2013","unstructured":"Alejandria MM, Lansang MAD, Dans LF, Mantaring Iii JB (2013) Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 9:CD001090","journal-title":"Cochrane Database Syst Rev"},{"key":"8_CR3","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/0090-1229(82)90022-8","volume":"22","author":"AJ Ammann","year":"1982","unstructured":"Ammann AJ, Ashman RF, Buckley RH et al (1982) Use of intravenous gamma-globulin in antibody immunodeficiency: results of a multicenter controlled trial. Clin Immunol Immunopathol 22:60\u201367","journal-title":"Clin Immunol Immunopathol"},{"key":"8_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1086\/511638","volume":"44","author":"DA Anaya","year":"2007","unstructured":"Anaya DA, Dellinger EP (2007) Necrotizing soft-tissue infection: diagnosis and management. Clin Infect Dis 44:705\u2013710","journal-title":"Clin Infect Dis"},{"key":"8_CR5","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1093\/infdis\/jix560","volume":"217","author":"F Andreoni","year":"2018","unstructured":"Andreoni F, Ugolini F, Keller N et al (2018) Immunoglobulin attenuates streptokinase-mediated virulence in Streptococcus dysgalactiae subspecies equisimilis necrotizing fasciitis. J Infect Dis 217:270\u2013279","journal-title":"J Infect Dis"},{"key":"8_CR6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1093\/cid\/cix639","volume":"65","author":"RJ Arciuolo","year":"2017","unstructured":"Arciuolo RJ, Jablonski RR, Zucker JR, Rosen JB (2017) Effectiveness of measles vaccination and immune globulin post-exposure prophylaxis in an outbreak setting-New York City, 2013. Clin Infect Dis 65:1843\u20131847","journal-title":"Clin Infect Dis"},{"key":"8_CR7","first-page":"2642","volume":"101","author":"B Arnholm","year":"2004","unstructured":"Arnholm B, Lundqvist A, Str\u00f6mberg A, Stromberg A (2004) High-dose immunoglobulin--life-saving in invasive group A streptococcal infection. Report of eleven cases with only one fatality. Lakartidningen 101:2642\u20132644","journal-title":"Lakartidningen"},{"key":"8_CR8","doi-asserted-by":"publisher","first-page":"101526","DOI":"10.1016\/j.tmaid.2019.101526","volume":"32","author":"HH Askling","year":"2019","unstructured":"Askling HH, Herzog C (2019) Hepatitis A vaccination in immunocompromised patients \u2013 the need for individualized vaccination strategies and correct methodology. Travel Med Infect Dis 32:101526","journal-title":"Travel Med Infect Dis"},{"key":"8_CR9","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1093\/infdis\/jiy110","volume":"218","author":"A Babbar","year":"2018","unstructured":"Babbar A, Bruun T, Hyldegaard O et al (2018) Pivotal role of preexisting pathogen-specific antibodies in the development of necrotizing soft-tissue infections. J Infect Dis 218:44\u201352","journal-title":"J Infect Dis"},{"key":"8_CR10","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2010.10.030","volume":"127","author":"M Ballow","year":"2011","unstructured":"Ballow M (2011) The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. J Allergy Clin Immunol 127:315\u2013323","journal-title":"J Allergy Clin Immunol"},{"key":"8_CR11","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1001\/jama.1992.03480240077038","volume":"267","author":"W Barry","year":"1992","unstructured":"Barry W, Hudgins L, Donta ST, Pesanti EL (1992) Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA 267:3315\u20133316","journal-title":"JAMA"},{"key":"8_CR12","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","volume":"76","author":"D Barth","year":"2011","unstructured":"Barth D, Nabavi Nouri M, Ng E et al (2011) Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76:2017\u20132023","journal-title":"Neurology"},{"key":"8_CR13","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1128\/IAI.66.5.2279-2283.1998","volume":"66","author":"H Basma","year":"1998","unstructured":"Basma H, Norrby-Teglund A, McGeer A et al (1998) Opsonic antibodies to the surface M protein of group A streptococci in pooled normal immunoglobulins (IVIG): potential impact on the clinical efficacy of IVIG therapy for severe invasive group A streptococcal infections. Infect Immun 66:2279\u20132283","journal-title":"Infect Immun"},{"key":"8_CR14","doi-asserted-by":"publisher","unstructured":"Bergsten H, Madsen MB, Bergey F et al (2020) Correlation between immunoglobulin dose administered and plasma neutralization of streptococcal superantigens in patients with necrotizing soft tissue infections. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa022","DOI":"10.1093\/cid\/ciaa022"},{"key":"8_CR15","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/joim.12265","volume":"276","author":"JF Bermejo-Mart\u00edn","year":"2014","unstructured":"Bermejo-Mart\u00edn JF, Rodriguez-Fernandez A, Herr\u00e1n-Monge R et al (2014) Immunoglobulins IgG1, IgM and IgA: a synergistic team influencing survival in sepsis. J Intern Med 276:404\u2013412","journal-title":"J Intern Med"},{"key":"8_CR16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/icb.1997.10","volume":"75","author":"CA Black","year":"1997","unstructured":"Black CA (1997) A brief history of the discovery of the immunoglobulins and the origin of the modern immunoglobulin nomenclature. Immunol Cell Biol 75:65\u201368","journal-title":"Immunol Cell Biol"},{"key":"8_CR17","unstructured":"Blood (2019) Criteria for the clinical use of intravenous immunoglobulin in Australia, 2nd ed. https:\/\/www.blood.gov.au\/pubs\/ivig\/intravenous-immunoglobulin-supply-and-demand.html. Accessed 23 Jan 2019"},{"key":"8_CR18","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.0105-2896.2005.00283.x","volume":"206","author":"P Brandtzaeg","year":"2005","unstructured":"Brandtzaeg P, Johansen F-E (2005) Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 206:32\u201363","journal-title":"Immunol Rev"},{"key":"8_CR19","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1001\/jama.1996.03540190035026","volume":"276","author":"JS Bresee","year":"1996","unstructured":"Bresee JS, Mast EE, Coleman PJ et al (1996) Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 276:1563\u20131567","journal-title":"JAMA"},{"key":"8_CR20","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/S1074-7613(03)00080-3","volume":"18","author":"P Bruhns","year":"2003","unstructured":"Bruhns P, Samuelsson A, Pollard JW, Ravetch JV (2003) Colony-stimulating factor-1-dependent macrophages are responsible for IVIG protection in antibody-induced autoimmune disease. Immunity 18:573\u2013581","journal-title":"Immunity"},{"key":"8_CR21","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1542\/peds.9.6.722","volume":"9","author":"OC Bruton","year":"1952","unstructured":"Bruton OC (1952) Agammaglobulinemia. Pediatrics 9:722\u2013728","journal-title":"Pediatrics"},{"key":"8_CR22","doi-asserted-by":"publisher","unstructured":"Bruun T, Rath E, Bruun Madsen M, et al (2020) Risk factors and predictors of mortality in streptococcal necrotizing soft-tissue Infections: a multicenter prospective study. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa027","DOI":"10.1093\/cid\/ciaa027"},{"key":"8_CR23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1164\/rccm.201608-1685OC","volume":"196","author":"KL Burnham","year":"2017","unstructured":"Burnham KL, Davenport EE, Radhakrishnan J et al (2017) Shared and distinct aspects of the sepsis transcriptomic response to fecal peritonitis and pneumonia. Am J Respir Crit Care Med 196:328\u2013339","journal-title":"Am J Respir Crit Care Med"},{"key":"8_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/0272-6386(95)90003-9","volume":"25","author":"TG Cant\u00fa","year":"1995","unstructured":"Cant\u00fa TG, Hoehn-Saric EW, Burgess KM et al (1995) Acute renal failure associated with immunoglobulin therapy. Am J Kidney Dis 25:228\u2013234","journal-title":"Am J Kidney Dis"},{"key":"8_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S1473-3099(05)70267-X","volume":"5","author":"JR Carapetis","year":"2005","unstructured":"Carapetis JR, Steer AC, Mulholland EK, Weber M (2005) The global burden of group A streptococcal diseases. Lancet Infect Dis 5:685\u2013694","journal-title":"Lancet Infect Dis"},{"key":"8_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/cid\/ciu304","volume":"59","author":"JR Carapetis","year":"2014","unstructured":"Carapetis JR, Jacoby P, Carville K et al (2014) Effectiveness of clindamycin and intravenous immunoglobulin, and risk of disease in contacts, in invasive group a streptococcal infections. Clin Infect Dis 59:358\u2013365","journal-title":"Clin Infect Dis"},{"key":"8_CR27","unstructured":"CDC (2020) Rabies postexposure prophylaxis (PEP)|Medical Care|Rabies|CDC. https:\/\/www.cdc.gov\/rabies\/medical_care\/index.html. Accessed 5 Feb 2020"},{"key":"8_CR28","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1182\/blood-2007-04-084061","volume":"111","author":"J Chang","year":"2008","unstructured":"Chang J, Shi PA, Chiang EY, Frenette PS (2008) Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood 111:915\u2013923","journal-title":"Blood"},{"issue":"Suppl","key":"8_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1046\/j.1365-2249.1999.00000.x","volume":"118","author":"HM Chapel","year":"1999","unstructured":"Chapel HM (1999) Safety and availability of immunoglobulin replacement therapy in relation to potentially transmissable agents. IUIS Committee on Primary Immunodeficiency Disease. Clin Exp Immunol 118(Suppl):29\u201334","journal-title":"Clin Exp Immunol"},{"key":"8_CR30","doi-asserted-by":"publisher","first-page":"3396","DOI":"10.1021\/ja01869a032","volume":"62","author":"EJ Cohn","year":"1940","unstructured":"Cohn EJ, Luetscher JA, Oncley JL et al (1940) Preparation and properties of serum and plasma proteins. III. Size and charge of proteins separating upon equilibration across membranes with ethanol\u2014water mixtures of controlled ph, ionic strength and temperature. J Am Chem Soc 62:3396\u20133400","journal-title":"J Am Chem Soc"},{"key":"8_CR31","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1086\/376630","volume":"37","author":"J Darenberg","year":"2003","unstructured":"Darenberg J, Ihendyane N, Sj\u00f6lin J et al (2003) Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis 37:333\u2013340","journal-title":"Clin Infect Dis"},{"key":"8_CR32","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1086\/381979","volume":"38","author":"J Darenberg","year":"2004","unstructured":"Darenberg J, Soderquist B, Normark BH, Norrby-Teglund A (2004) Differences in potency of intravenous polyspecific immunoglobulin G against streptococcal and staphylococcal superantigens: implications for therapy of toxic shock syndrome. Clin Infect Dis 38:836\u2013842","journal-title":"Clin Infect Dis"},{"key":"8_CR33","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1128\/IAI.65.2.366-372.1997","volume":"65","author":"T Darville","year":"1997","unstructured":"Darville T, Milligan LB, Laffoon KK (1997) Intravenous immunoglobulin inhibits staphylococcal toxin-induced human mononuclear phagocyte tumor necrosis factor alpha production. Infect Immun 65:366\u2013372","journal-title":"Infect Immun"},{"key":"8_CR34","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s00134-015-3916-9","volume":"41","author":"N de Prost","year":"2015","unstructured":"de Prost N, Sbidian E, Chosidow O et al (2015) Management of necrotizing soft tissue infections in the intensive care unit: results of an international survey. Intensive Care Med 41:1506\u20131508","journal-title":"Intensive Care Med"},{"key":"8_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1423-0410.2012.01648.x","volume":"104","author":"F Dhainaut","year":"2013","unstructured":"Dhainaut F, Guillaumat P-O, Dib H et al (2013) In vitro and in vivo properties differ among liquid intravenous immunoglobulin preparations. Vox Sang 104:115\u2013126","journal-title":"Vox Sang"},{"key":"8_CR36","doi-asserted-by":"publisher","unstructured":"Di Rosa R, Pietrosanti M, Luzi G, Salemi S (2014) Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis? https:\/\/doi.org\/10.1016\/j.ejim.2014.05.002","DOI":"10.1016\/j.ejim.2014.05.002"},{"key":"8_CR37","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1126\/scitranslmed.aag1153","volume":"8","author":"BA Diep","year":"2016","unstructured":"Diep BA, Le VTM, Badiou C et al (2016) IVIG-mediated protection against necrotizing pneumonia caused by MRSA. Sci Transl Med 8:357","journal-title":"Sci Transl Med"},{"key":"8_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0141588","volume":"10","author":"P Egerup","year":"2015","unstructured":"Egerup P, Lindschou J, Gluud C, Christiansen OB (2015) The effects of intravenous immunoglobulins in women with recurrent miscarriages: A systematic review of randomised trials with meta-analyses and trial sequential analyses including individual patient data. PLoS One 10:e0141588","journal-title":"PLoS One"},{"key":"8_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1136\/archdischild-2012-302841","volume":"99","author":"D Eleftheriou","year":"2014","unstructured":"Eleftheriou D, Levin M, Shingadia D et al (2014) Management of Kawasaki disease. Arch Dis Child 99:74\u201383","journal-title":"Arch Dis Child"},{"key":"8_CR40","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ttbdis.2016.11.007","volume":"8","author":"J Elsterova","year":"2017","unstructured":"Elsterova J, Palus M, Sirmarova J et al (2017) Tick-borne encephalitis virus neutralization by high dose intravenous immunoglobulin. Ticks Tick Borne Dis 8:253\u2013258","journal-title":"Ticks Tick Borne Dis"},{"key":"8_CR41","doi-asserted-by":"publisher","first-page":"25923","DOI":"10.1073\/pnas.1910883116","volume":"116","author":"J Emg\u00e5rd","year":"2019","unstructured":"Emg\u00e5rd J, Bergsten H, McCormick JK et al (2019) MAIT cells are major contributors to the cytokine response in group A streptococcal toxic shock syndrome. Proc Natl Acad Sci U S A 116:25923\u201325931","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8_CR42","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1182\/blood-2007-03-079947","volume":"111","author":"A Ephrem","year":"2008","unstructured":"Ephrem A, Chamat S, Miquel C et al (2008) Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis. Blood 111:715\u2013722","journal-title":"Blood"},{"key":"8_CR43","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1086\/314872","volume":"180","author":"BK Eriksson","year":"1999","unstructured":"Eriksson BK, Andersson J, Holm SE, Norgren M (1999) Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome. J Infect Dis 180:410\u2013418","journal-title":"J Infect Dis"},{"key":"8_CR44","unstructured":"European Medicines Agency (2020) Clinical investigation of human normal immunoglobulin for intravenous administration (IVIg). https:\/\/www.ema.europa.eu\/en\/clinical-investigation-human-normal-immunoglobulin-intravenous-administration-ivig#current-effective-version-section. Accessed 19 Feb 2020"},{"key":"8_CR45","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s10096-013-1861-5","volume":"32","author":"N Farag","year":"2013","unstructured":"Farag N, Mahran L, Abou-Aisha K, El-Azizi M (2013) Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo. Eur J Clin Microbiol Infect Dis 32:1149\u20131160","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"8_CR46","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3389\/fimmu.2014.00665","volume":"5","author":"A Farrugia","year":"2014","unstructured":"Farrugia A, Quinti I (2014) Manufacture of immunoglobulin products for patients with primary antibody deficiencies - the effect of processing conditions on product safety and efficacy. Front Immunol 5:665","journal-title":"Front Immunol"},{"key":"8_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s10730-014-9253-5","volume":"27","author":"A Farrugia","year":"2015","unstructured":"Farrugia A, Penrod J, Bult JM (2015) The ethics of paid plasma donation: a plea for patient centeredness. HEC Forum 27:417\u2013429","journal-title":"HEC Forum"},{"key":"8_CR48","unstructured":"FASS (2020) FASS Allm\u00e4nhet - Startsida. https:\/\/www.fass.se\/LIF\/startpage. Accessed 19 Feb 2020"},{"key":"8_CR49","unstructured":"FDA (2019) Fractionated plasma products - immune globulins. https:\/\/www.fda.gov\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/FractionatedPlasmaProducts\/ucm127589.htm. Accessed 24 Jan 2019"},{"key":"8_CR50","first-page":"S16","volume":"9","author":"A Ferrante","year":"1990","unstructured":"Ferrante A, Beard LJ, Feldman RG (1990) IgG subclass distribution of antibodies to bacteria and viral antigens. Pediatr Infect Dis J 9:S16\u2013S24","journal-title":"Pediatr Infect Dis J"},{"key":"8_CR51","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1600-0404.2005.00448.x","volume":"112","author":"J Finsterer","year":"2005","unstructured":"Finsterer J (2005) Treatment of immune-mediated, dysimmune neuropathies. Acta Neurol Scand 112:115\u2013125","journal-title":"Acta Neurol Scand"},{"key":"8_CR52","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-3148.2010.01022.x","volume":"20","author":"R Foster","year":"2010","unstructured":"Foster R, Suri A, Filate W et al (2010) Use of intravenous immune globulin in the ICU: a retrospective review of prescribing practices and patient outcomes. Transfus Med 20:403\u2013408","journal-title":"Transfus Med"},{"key":"8_CR53","first-page":"8","volume":"76","author":"ND Garbett","year":"1989","unstructured":"Garbett ND, Munro CS, Cole PJ (1989) Opsonic activity of a new intravenous immunoglobulin preparation: Pentaglobin compared with sandoglobulin. Clin Exp Immunol 76:8\u201312","journal-title":"Clin Exp Immunol"},{"key":"8_CR54","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","volume":"6","author":"M Garc\u00eda-Carrasco","year":"2007","unstructured":"Garc\u00eda-Carrasco M, Esc\u00e1rcega RO, Fuentes-Alexandro S et al (2007) Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 6:373\u2013378","journal-title":"Autoimmun Rev"},{"key":"8_CR55","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1086\/380909","volume":"189","author":"V Gauduchon","year":"2004","unstructured":"Gauduchon V, Cozon G, Vandenesch F et al (2004) Neutralization of Staphylococcus aureus panton valentine leukocidin by intravenous immunoglobulin in vitro. J Infect Dis 189:346\u2013353","journal-title":"J Infect Dis"},{"key":"8_CR56","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1056\/NEJMra1009433","volume":"367","author":"EW Gelfand","year":"2012","unstructured":"Gelfand EW (2012) Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 367:2015\u20132025","journal-title":"N Engl J Med"},{"key":"8_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0002-9343(87)90543-2","volume":"83","author":"DS Gordon","year":"1987","unstructured":"Gordon DS (1987) Intravenous immunoglobulin: historical perspective. Am J Med 83:1\u20133","journal-title":"Am J Med"},{"key":"8_CR58","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1097\/00006534-199905000-00003","volume":"103","author":"CT Haywood","year":"1999","unstructured":"Haywood CT, McGeer A, Low DE et al (1999) Clinical experience with 20 cases of group A streptococcus necrotizing fasciitis and myonecrosis: 1995 to 1997. Plast Reconstr Surg 103:1567\u20131573","journal-title":"Plast Reconstr Surg"},{"key":"8_CR59","volume":"5","author":"C Hua","year":"2018","unstructured":"Hua C, Bosc R, Sbidian E et al (2018) Interventions for necrotizing soft tissue infections in adults. Cochrane Database Syst Rev 5:CD011680","journal-title":"Cochrane Database Syst Rev"},{"key":"8_CR60","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1016\/S0140-6736(81)92400-4","volume":"1","author":"P Imbach","year":"1981","unstructured":"Imbach P, Barandun S, d\u2019Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228\u20131231","journal-title":"Lancet"},{"key":"8_CR61","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s12185-015-1785-1","volume":"101","author":"MO Jamil","year":"2015","unstructured":"Jamil MO, Mineishi S (2015) State-of-the-art acute and chronic GVHD treatment. Int J Hematol 101:452\u2013466","journal-title":"Int J Hematol"},{"key":"8_CR62","doi-asserted-by":"crossref","unstructured":"Johansson L, Norrby-Teglund A (2012) Immunopathogenesis of streptococcal deep tissue infections. In: Current topics in microbiology and immunology. pp 173\u2013188","DOI":"10.1007\/82_2012_282"},{"key":"8_CR63","first-page":"877","volume":"64","author":"SS Kadri","year":"2017","unstructured":"Kadri SS, Swihart BJ, Bonne SL et al (2017) Impact of intravenous immunoglobulin on survival in necrotizing fasciitis with vasopressor-dependent shock: a propensity score-matched analysis from 130 US hospitals. Clin Infect Dis 64:877\u2013885","journal-title":"Clin Infect Dis"},{"key":"8_CR64","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jcrc.2018.06.005","volume":"47","author":"L Kakoullis","year":"2018","unstructured":"Kakoullis L, Pantzaris N-D, Platanaki C et al (2018) The use of IgM-enriched immunoglobulin in adult patients with sepsis. J Crit Care 47:30\u201335","journal-title":"J Crit Care"},{"key":"8_CR65","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1097\/CCM.0b013e318236f473","volume":"40","author":"SL Kane-Gill","year":"2012","unstructured":"Kane-Gill SL, Kirisci L, Verrico MM, Rothschild JM (2012) Analysis of risk factors for adverse drug events in critically ill patients. Crit Care Med 40:823\u2013828","journal-title":"Crit Care Med"},{"key":"8_CR66","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1084\/jem.20051900","volume":"203","author":"Y Kaneko","year":"2006","unstructured":"Kaneko Y, Nimmerjahn F, Madaio MP, Ravetch JV (2006) Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203:789\u2013797","journal-title":"J Exp Med"},{"key":"8_CR67","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1086\/515199","volume":"28","author":"R Kaul","year":"1999","unstructured":"Kaul R, McGeer A, Norrby-Teglund A et al (1999) Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. Clin Infect Dis 28:800\u2013807","journal-title":"Clin Infect Dis"},{"key":"8_CR68","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1172\/JCI24394","volume":"115","author":"N Li","year":"2005","unstructured":"Li N, Zhao M, Hilario-Vargas J et al (2005) Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. J Clin Invest 115:3440\u20133450","journal-title":"J Clin Invest"},{"key":"8_CR69","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1093\/cid\/ciu449","volume":"59","author":"A Linn\u00e9r","year":"2014","unstructured":"Linn\u00e9r A, Darenberg J, Sj\u00f6lin J et al (2014) Clinical efficacy of polyspecific intravenous immunoglobulin therapy in patients with streptococcal toxic shock syndrome: a comparative observational study. Clin Infect Dis 59:851\u2013857","journal-title":"Clin Infect Dis"},{"key":"8_CR70","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s00134-017-4786-0","volume":"43","author":"MB Madsen","year":"2017","unstructured":"Madsen MB, Hjortrup PB, Hansen MB et al (2017) Immunoglobulin G for patients with necrotising soft tissue infection (INSTINCT): a randomised, blinded, placebo-controlled trial. Intensive Care Med 43:1585\u20131593","journal-title":"Intensive Care Med"},{"key":"8_CR71","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1007\/s00134-019-05730-x","volume":"45","author":"MB Madsen","year":"2019","unstructured":"Madsen MB, Skrede S, Perner A et al (2019) Patient\u2019s characteristics and outcomes in necrotising soft-tissue infections: results from a Scandinavian, multicentre, prospective cohort study. Intensive Care Med 45:1241\u20131251","journal-title":"Intensive Care Med"},{"key":"8_CR72","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1242\/dmm.021923","volume":"8","author":"S Mairpady Shambat","year":"2015","unstructured":"Mairpady Shambat S, Chen P, Nguyen Hoang AT et al (2015) Modelling staphylococcal pneumonia in a human 3D lung tissue model system delineates toxin-mediated pathology. Dis Model Mech 8:1413\u20131425","journal-title":"Dis Model Mech"},{"key":"8_CR73","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13613-017-0268-3","volume":"7","author":"I Martin-Loeches","year":"2017","unstructured":"Martin-Loeches I, Muriel-Bomb\u00edn A, Ferrer R et al (2017) The protective association of endogenous immunoglobulins against sepsis mortality is restricted to patients with moderate organ failure. Ann Intensive Care 7:44","journal-title":"Ann Intensive Care"},{"key":"8_CR74","doi-asserted-by":"publisher","first-page":"7916","DOI":"10.1016\/j.vaccine.2018.10.070","volume":"36","author":"D Matysiak-Klose","year":"2018","unstructured":"Matysiak-Klose D, Santibanez S, Schwerdtfeger C et al (2018) Post-exposure prophylaxis for measles with immunoglobulins revised recommendations of the standing committee on vaccination in Germany. Vaccine 36:7916\u20137922","journal-title":"Vaccine"},{"key":"8_CR75","unstructured":"Medicines Agency E (2018) Committee for Medicinal Products for Human Use (CHMP) Guideline on the clinical investigation of human normal immunoglobulin for intravenous administration (IVIg)"},{"key":"8_CR76","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0012-3692(15)50887-8","volume":"130","author":"S Mehta","year":"2006","unstructured":"Mehta S, McGeer A, Low DE et al (2006) Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU. Chest 130:1679\u20131686","journal-title":"Chest"},{"key":"8_CR77","unstructured":"NHS (2019) Tests we carry out - NHS Blood Donation. https:\/\/www.blood.co.uk\/the-donation-process\/further-information\/tests-we-carry-out\/. Accessed 11 Nov 2019"},{"key":"8_CR78","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1001\/jama.1990.03450240091046","volume":"264","author":"NIH","year":"1990","unstructured":"NIH (1990) NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 264:3189\u20133193","journal-title":"JAMA"},{"key":"8_CR79","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/infdis\/170.3.585","volume":"170","author":"A Norrby-Teglund","year":"1994","unstructured":"Norrby-Teglund A, Pauksens K, Holm SE, Norgren M (1994) Relation between low capacity of human sera to inhibit streptococcal mitogens and serious manifestation of disease. J Infect Dis 170:585\u2013591","journal-title":"J Infect Dis"},{"key":"8_CR80","doi-asserted-by":"publisher","first-page":"5395","DOI":"10.1128\/IAI.64.12.5395-5398.1996","volume":"64","author":"A Norrby-Teglund","year":"1996","unstructured":"Norrby-Teglund A, Kaul R, Low DE et al (1996a) Evidence for the presence of streptococcal-superantigen-neutralizing antibodies in normal polyspecific immunoglobulin G. Infect Immun 64:5395\u20135398","journal-title":"Infect Immun"},{"key":"8_CR81","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.4049\/jimmunol.156.8.3057","volume":"156","author":"A Norrby-Teglund","year":"1996","unstructured":"Norrby-Teglund A, Kaul R, Low DE et al (1996b) Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production. J Immunol 156:3057\u20133064","journal-title":"J Immunol"},{"key":"8_CR82","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1086\/514588","volume":"26","author":"A Norrby-Teglund","year":"1998","unstructured":"Norrby-Teglund A, Basma H, Andersson J et al (1998) Varying titers of neutralizing antibodies to streptococcal superantigens in different preparations of normal polyspecific immunoglobulin G: implications for therapeutic efficacy. Clin Infect Dis 26:631\u2013638","journal-title":"Clin Infect Dis"},{"key":"8_CR83","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1002\/1521-4141(200011)30:11<3247::AID-IMMU3247>3.0.CO;2-D","volume":"30","author":"A Norrby-Teglund","year":"2000","unstructured":"Norrby-Teglund A, Chatellier S, Low DE et al (2000) Host variation in cytokine responses to superantigens determine the severity of invasive group A streptococcal infection. Eur J Immunol 30:3247\u20133255","journal-title":"Eur J Immunol"},{"key":"8_CR84","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/00365540310015944","volume":"35","author":"A Norrby-Teglund","year":"2003","unstructured":"Norrby-Teglund A, Ihendyane N, Darenberg J (2003) Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis 35:683\u2013689","journal-title":"Scand J Infect Dis"},{"key":"8_CR85","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/00365540410020866","volume":"37","author":"A Norrby-Teglund","year":"2005","unstructured":"Norrby-Teglund A, Muller MP, Mcgeer A et al (2005) Successful management of severe group A streptococcal soft tissue infections using an aggressive medical regimen including intravenous polyspecific immunoglobulin together with a conservative surgical approach. Scand J Infect Dis 37:166\u2013172","journal-title":"Scand J Infect Dis"},{"key":"8_CR86","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2165\/00002018-199921030-00003","volume":"21","author":"UE Nydegger","year":"1999","unstructured":"Nydegger UE, Sturzenegger M (1999) Adverse effects of intravenous immunoglobulin therapy. Drug Saf 21:171\u2013185","journal-title":"Drug Saf"},{"key":"8_CR87","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1056\/NEJM199107113250207","volume":"325","author":"JA Oates","year":"1991","unstructured":"Oates JA, Wood AJ, Buckley RH, Schiff RI (1991) The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325:110\u2013117","journal-title":"N Engl J Med"},{"key":"8_CR88","first-page":"CD000361","volume":"1","author":"A Ohlsson","year":"2020","unstructured":"Ohlsson A, Lacy JB (2020) Intravenous immunoglobulin for preventing infection in preterm and\/or low birth weight infants. Cochrane Database Syst Rev 1:CD000361","journal-title":"Cochrane Database Syst Rev"},{"key":"8_CR89","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/cid\/ciy401","volume":"67","author":"T Parks","year":"2018","unstructured":"Parks T, Wilson C, Curtis N et al (2018) Polyspecific intravenous immunoglobulin in clindamycin-treated patients with streptococcal toxic shock syndrome: a systematic review and meta-analysis. Clin Infect Dis 67:1434\u20131436","journal-title":"Clin Infect Dis"},{"key":"8_CR90","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","volume":"354","author":"SJ Perlmutter","year":"1999","unstructured":"Perlmutter SJ, Leitman SF, Garvey MA et al (1999) Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 354:1153\u20131158","journal-title":"Lancet"},{"key":"8_CR91","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","volume":"17","author":"LR Pierce","year":"2003","unstructured":"Pierce LR, Jain N (2003) Risks associated with the use of intravenous immunoglobulin. Transfus Med Rev 17:241\u2013251","journal-title":"Transfus Med Rev"},{"key":"8_CR92","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1086\/421089","volume":"39","author":"J Pildal","year":"2004","unstructured":"Pildal J, Gotzsche PC (2004) Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 39:38\u201346","journal-title":"Clin Infect Dis"},{"key":"8_CR93","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/S0140-6736(94)90679-3","volume":"344","author":"JP Power","year":"1994","unstructured":"Power JP, Lawlor E, Davidson F et al (1994) Hepatitis C viraemia in recipients of Irish intravenous anti-D immunoglobulin. Lancet 344:1166\u20131167","journal-title":"Lancet"},{"key":"8_CR94","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1080\/10428190902856824","volume":"50","author":"P Raanani","year":"2009","unstructured":"Raanani P, Gafter-Gvili A, Paul M et al (2009) Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis. Leuk Lymphoma 50:764\u2013772","journal-title":"Leuk Lymphoma"},{"key":"8_CR95","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","volume":"98","author":"M Radosevich","year":"2010","unstructured":"Radosevich M, Burnouf T (2010) Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance. Vox Sang 98:12\u201328","journal-title":"Vox Sang"},{"key":"8_CR96","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13104-019-4262-8","volume":"12","author":"M Reglinski","year":"2019","unstructured":"Reglinski M, Sriskandan S (2019) Treatment potential of pathogen-reactive antibodies sequentially purified from pooled human immunoglobulin. BMC Res Notes 12:228","journal-title":"BMC Res Notes"},{"key":"8_CR97","doi-asserted-by":"publisher","first-page":"15825","DOI":"10.1038\/srep15825","volume":"5","author":"M Reglinski","year":"2015","unstructured":"Reglinski M, Gierula M, Lynskey NN et al (2015) Identification of the Streptococcus pyogenes surface antigens recognised by pooled human immunoglobulin. Sci Rep 5:15825","journal-title":"Sci Rep"},{"key":"8_CR98","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s00134-017-4683-6","volume":"43","author":"A Rhodes","year":"2017","unstructured":"Rhodes A, Evans LE, Alhazzani W et al (2017) Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 43:304\u2013377","journal-title":"Intensive Care Med"},{"key":"8_CR99","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2105\/AJPH.25.12.1353","volume":"25","author":"ES Robinson","year":"1935","unstructured":"Robinson ES, McKhann CF (1935) Immunological application of placental extracts. Am J Public Health Nations Health 25:1353\u20131358","journal-title":"Am J Public Health Nations Health"},{"key":"8_CR100","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1097\/01.shk.0000157302.69125.f8","volume":"23","author":"A Rodr\u00edguez","year":"2005","unstructured":"Rodr\u00edguez A, Rello J, Neira J et al (2005) Effects of high-dose of intravenous immunoglobulin and antibiotics on survival for severe sepsis undergoing surgery. Shock 23:298\u2013304","journal-title":"Shock"},{"key":"8_CR101","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1126\/science.291.5503.484","volume":"291","author":"A Samuelsson","year":"2001","unstructured":"Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484\u2013486","journal-title":"Science"},{"key":"8_CR102","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1086\/507037","volume":"43","author":"B Schrage","year":"2006","unstructured":"Schrage B, Duan G, Yang LP et al (2006) Different preparations of intravenous immunoglobulin vary in their efficacy to neutralize streptococcal superantigens: implications for treatment of streptococcal toxic shock syndrome. Clin Infect Dis 43:743\u2013746","journal-title":"Clin Infect Dis"},{"key":"8_CR103","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.jaci.2009.09.046","volume":"125","author":"HW Schroeder","year":"2010","unstructured":"Schroeder HW, Cavacini L (2010) Structure and function of immunoglobulins. J Allergy Clin Immunol 125:S41\u2013S52","journal-title":"J Allergy Clin Immunol"},{"key":"8_CR104","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176\u2013189","journal-title":"Nat Rev Immunol"},{"key":"8_CR105","doi-asserted-by":"publisher","first-page":"259","DOI":"10.7326\/0003-4819-121-4-199408150-00004","volume":"121","author":"EA Sekul","year":"1994","unstructured":"Sekul EA, Cupler EJ, Dalakas MC (1994) Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 121:259\u2013262","journal-title":"Ann Intern Med"},{"key":"8_CR106","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/cc10597","volume":"16","author":"M Shankar-Hari","year":"2012","unstructured":"Shankar-Hari M, Spencer J, Sewell WA et al (2012) Bench-to-bedside review: immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care 16:206","journal-title":"Crit Care"},{"key":"8_CR107","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1097\/CCM.0000000000001876","volume":"44","author":"M Shankar-Hari","year":"2016","unstructured":"Shankar-Hari M, Harrison DA, Rowan KM (2016) Differences in impact of definitional elements on mortality precludes international comparisons of sepsis epidemiology\u2014a cohort study illustrating the need for standardized reporting. Crit Care Med 44:2223\u20132230","journal-title":"Crit Care Med"},{"key":"8_CR108","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00134-018-5047-6","volume":"44","author":"M Shankar-Hari","year":"2018","unstructured":"Shankar-Hari M, Madsen MB, Turgeon AF (2018) Immunoglobulins and sepsis. Intensive Care Med 44:1923\u20131925","journal-title":"Intensive Care Med"},{"key":"8_CR109","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1056\/NEJM198007243030402","volume":"303","author":"GR Siber","year":"1980","unstructured":"Siber GR, Schur PH, Aisenberg AC et al (1980) Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 303:178\u2013182","journal-title":"N Engl J Med"},{"key":"8_CR110","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.intimp.2005.11.004","volume":"6","author":"J Siegel","year":"2006","unstructured":"Siegel J (2006) Safety considerations in IGIV utilization. Int Immunopharmacol 6:523\u2013527","journal-title":"Int Immunopharmacol"},{"key":"8_CR111","unstructured":"Siegel J (2015) Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations"},{"key":"8_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta16070","volume":"16","author":"M Soares","year":"2012","unstructured":"Soares M, Welton N, Harrison D et al (2012) An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of informati. Health Technol Assess 16:1\u2013186","journal-title":"Health Technol Assess"},{"key":"8_CR113","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/jac\/dkl173","volume":"58","author":"S Sriskandan","year":"2006","unstructured":"Sriskandan S, Ferguson M, Elliot V et al (2006) Human intravenous immunoglobulin for experimental streptococcal toxic shock: bacterial clearance and modulation of inflammation. J Antimicrob Chemother 58:117\u2013124","journal-title":"J Antimicrob Chemother"},{"key":"8_CR114","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3109\/00365549209054644","volume":"24","author":"B Stegmayr","year":"1992","unstructured":"Stegmayr B, Bj\u00f6rck S, Holm S et al (1992) Septic shock induced by group A streptococcal infection: clinical and therapeutic aspects. Scand J Infect Dis 24:589\u2013597","journal-title":"Scand J Infect Dis"},{"key":"8_CR115","first-page":"476","volume":"107","author":"F Steinhagen","year":"2020","unstructured":"Steinhagen F, Schmidt SV, Schewe J-C et al (2020) Immunotherapy in sepsis - brake or accelerate? Pharmacol Ther 107:476","journal-title":"Pharmacol Ther"},{"key":"8_CR116","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0140-6736(84)90701-3","volume":"2","author":"Y Sultan","year":"1984","unstructured":"Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE (1984) Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 2:765\u2013768","journal-title":"Lancet"},{"key":"8_CR117","unstructured":"Sundhedstyrelsen (2016) Redeg\u00f8relse for blodproduktomr\u00e5det 2015"},{"key":"8_CR118","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1172\/JCI116240","volume":"91","author":"S Takei","year":"1993","unstructured":"Takei S, Arora YK, Walker SM (1993) Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 91:602\u2013607","journal-title":"J Clin Invest"},{"key":"8_CR119","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.cmi.2018.07.007","volume":"25","author":"A Tarnutzer","year":"2019","unstructured":"Tarnutzer A, Andreoni F, Keller N et al (2019) Human polyspecific immunoglobulin attenuates group A streptococcal virulence factor activity and reduces disease severity in a murine necrotizing fasciitis model. Clin Microbiol Infect 25:512","journal-title":"Clin Microbiol Infect"},{"key":"8_CR120","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1046\/j.1365-2249.1998.00445.x","volume":"111","author":"M Trautmann","year":"1998","unstructured":"Trautmann M, Held TK, Susa M et al (1998) Bacterial lipopolysaccharide (LPS)-specific antibodies in commercial human immunoglobulin preparations: superior antibody content of an IgM-enriched product. Clin Exp Immunol 111:81\u201390","journal-title":"Clin Exp Immunol"},{"key":"8_CR121","doi-asserted-by":"publisher","first-page":"226","DOI":"10.14745\/ccdr.v44i09a07","volume":"44","author":"MC Tunis","year":"2018","unstructured":"Tunis MC, Salvadori MI, Dubey V et al (2018) Updated NACI recommendations for measles post-exposure prophylaxis. Can Commun Dis Rep 44:226\u2013230","journal-title":"Can Commun Dis Rep"},{"key":"8_CR122","doi-asserted-by":"publisher","first-page":"193","DOI":"10.7326\/0003-4819-146-3-200702060-00009","volume":"146","author":"AF Turgeon","year":"2007","unstructured":"Turgeon AF, Hutton B, Fergusson DA et al (2007) Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis. Ann Intern Med 146:193\u2013203","journal-title":"Ann Intern Med"},{"key":"8_CR123","doi-asserted-by":"publisher","unstructured":"Vanderven HA, Kent SJ (2020) The protective potential of Fc-mediated antibody functions against influenza virus and other viral pathogens. Immunol Cell Biol. https:\/\/doi.org\/10.1111\/imcb.12312","DOI":"10.1111\/imcb.12312"},{"key":"8_CR124","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1126\/science.282.5388.490","volume":"282","author":"I Viard","year":"1998","unstructured":"Viard I, Wehrli P, Bullani R et al (1998) Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282:490\u2013493","journal-title":"Science"},{"key":"8_CR125","doi-asserted-by":"publisher","first-page":"520","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T (2014) IgG subclasses and allotypes: from structure to effector functions. Front Immunol 5:520","journal-title":"Front Immunol"},{"key":"8_CR126","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12016-014-8408-0","volume":"48","author":"A Wade","year":"2015","unstructured":"Wade A, Chang C (2015) Evaluation and treatment of critical asthma syndrome in children. Clin Rev Allergy Immunol 48:66\u201383","journal-title":"Clin Rev Allergy Immunol"},{"key":"8_CR127","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne CD, Jew J (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473\u2013483","journal-title":"Med Care"},{"key":"8_CR128","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s00134-018-5143-7","volume":"44","author":"T Welte","year":"2018","unstructured":"Welte T, Dellinger RP, Ebelt H et al (2018) Efficacy and safety of trimodulin, a novel polyclonal antibody preparation, in patients with severe community-acquired pneumonia: a randomized, placebo-controlled, double-blind, multicenter, phase II trial (CIGMA study). Intensive Care Med 44:438\u2013448","journal-title":"Intensive Care Med"},{"key":"8_CR129","doi-asserted-by":"publisher","first-page":"2693","DOI":"10.1097\/00003246-200712000-00026","volume":"35","author":"K Werdan","year":"2007","unstructured":"Werdan K, Pilz G, Bujdoso O et al (2007) Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit Care Med 35:2693\u20132701","journal-title":"Crit Care Med"},{"key":"8_CR130","unstructured":"WHO (2020) Quality assurance and safety: blood products and related biologicals. https:\/\/www.who.int\/bloodproducts\/en\/. Accessed 5 Feb 2020"},{"key":"8_CR131","doi-asserted-by":"publisher","first-page":"e00968","DOI":"10.1128\/AAC.00968-17","volume":"61","author":"JB Wood","year":"2017","unstructured":"Wood JB, Jones LS, Soper NR et al (2017) Commercial intravenous immunoglobulin preparations contain functional neutralizing antibodies against the Staphylococcus aureus leukocidin LukAB (LukGH). Antimicrob Agents Chemother 61:e00968","journal-title":"Antimicrob Agents Chemother"},{"key":"8_CR132","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1002\/path.1877","volume":"208","author":"JM Woof","year":"2006","unstructured":"Woof JM, Kerr MA (2006) The function of immunoglobulin A in immunity. J Pathol 208:270\u2013282","journal-title":"J Pathol"},{"key":"8_CR133","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","volume":"68","author":"L Zinman","year":"2007","unstructured":"Zinman L, Ng E, Bril V (2007) IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 68:837\u2013841","journal-title":"Neurology"}],"container-title":["Advances in Experimental Medicine and Biology","Necrotizing Soft Tissue Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-57616-5_8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T05:33:08Z","timestamp":1696915988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-57616-5_8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9783030576158","9783030576165"],"references-count":133,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-57616-5_8","relation":{},"ISSN":["0065-2598","2214-8019"],"issn-type":[{"value":"0065-2598","type":"print"},{"value":"2214-8019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]},"assertion":[{"value":"21 October 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}